ES2092316T3 - Agentes antianginosos de purinona. - Google Patents

Agentes antianginosos de purinona.

Info

Publication number
ES2092316T3
ES2092316T3 ES93914675T ES93914675T ES2092316T3 ES 2092316 T3 ES2092316 T3 ES 2092316T3 ES 93914675 T ES93914675 T ES 93914675T ES 93914675 T ES93914675 T ES 93914675T ES 2092316 T3 ES2092316 T3 ES 2092316T3
Authority
ES
Spain
Prior art keywords
alkyl
purinona
angulous
agents
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93914675T
Other languages
English (en)
Inventor
Nicholas Kenneth Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2092316T3 publication Critical patent/ES2092316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Paper (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Vending Machines For Individual Products (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) Y LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R1 ES ALQUILO C1-C4; R2 ES ALQUILO C2-C4; R3 ES H O SO2NR4R5; R4 Y R5 JUNTO CON EL ATOMO DE NITROGENO AL CUAL ESTAN UNIDAS FORMAN UN GRUPO DE PIRROLIDINO, PIPERIDINO, MORFOLINO O 4-N-(R6)-1-PIPERAZINIL; Y R6 ES H O ALQUILO C1-C3; LOS COMPUESTOS SON INHIBIDORES SELECTIVOS DEL CGMP PDE UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES TALES COMO LA ANGINA, LA HIPERTENSION, EL FALLO CARDIACO Y LA ARTERIOSCLEROSIS.
ES93914675T 1992-06-26 1993-06-18 Agentes antianginosos de purinona. Expired - Lifetime ES2092316T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929213623A GB9213623D0 (en) 1992-06-26 1992-06-26 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2092316T3 true ES2092316T3 (es) 1996-11-16

Family

ID=10717795

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93914675T Expired - Lifetime ES2092316T3 (es) 1992-06-26 1993-06-18 Agentes antianginosos de purinona.

Country Status (11)

Country Link
EP (1) EP0647227B1 (es)
JP (1) JP2544903B2 (es)
AT (1) ATE143961T1 (es)
CA (1) CA2139109C (es)
DE (1) DE69305344T2 (es)
DK (1) DK0647227T3 (es)
ES (1) ES2092316T3 (es)
FI (1) FI946083A0 (es)
GB (1) GB9213623D0 (es)
GR (1) GR3021878T3 (es)
WO (1) WO1994000453A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951367A7 (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
JPH1087666A (ja) * 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法
DE19702785A1 (de) * 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
HRP20000712A2 (en) 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
AU4501199A (en) * 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
EP1261609B1 (de) 1999-12-24 2004-11-03 Bayer HealthCare AG Triazolotriazinone und ihre verwendung
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
DE60235198D1 (de) 2001-12-20 2010-03-11 Merck Serono Sa Coinsins Pyrrolidin-derivatie als prostaglandin-modulatoren
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
WO2006100557A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
WO1994000453A1 (en) 1994-01-06
CA2139109C (en) 1997-03-25
FI946083A7 (fi) 1994-12-23
DE69305344D1 (de) 1996-11-14
EP0647227A1 (en) 1995-04-12
DE69305344T2 (de) 1997-02-20
JP2544903B2 (ja) 1996-10-16
FI946083L (fi) 1994-12-23
CA2139109A1 (en) 1994-01-06
ATE143961T1 (de) 1996-10-15
FI946083A0 (fi) 1994-12-23
GR3021878T3 (en) 1997-03-31
DK0647227T3 (da) 1996-11-18
JPH07504681A (ja) 1995-05-25
EP0647227B1 (en) 1996-10-09
GB9213623D0 (en) 1992-08-12

Similar Documents

Publication Publication Date Title
ES2092316T3 (es) Agentes antianginosos de purinona.
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
ES2071919T3 (es) Agentes antianginosos de pirazolopirimidina.
ECSP045368A (es) "antagonistas de los receptores de trombina"
ES2096936T3 (es) Agentes antianginales de piridopirimidinona.
CO5680403A2 (es) Antagonistas de mchr1r
ES2183905T3 (es) Inhibidores de metaloproteasa de matriz.
EA200400550A1 (ru) Бициклические производные оксопиридина и оксопиримидина
CO5601002A2 (es) Inhibidores de la acc
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5570668A2 (es) Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen
ES2107506T3 (es) Pirazolopirimidonas como agentes antianginosos.
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
ES476535A1 (es) Un procedimiento para la preparacion de nuevos derivados de acidos pirrol-1-carboxilicos.
EA200000400A1 (ru) Галогензамещенные тетрациклические производные тетрагидрофурана
ES2136291T3 (es) Derivados de pirimidina.
ES2085330T3 (es) Eteres ciclicos heterociclicos con actividad inhibidora de 5-lipoxigenasa.
EA200400545A1 (ru) Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
ES2123873T3 (es) Pirrolocarbazol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 647227

Country of ref document: ES